Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma

Launched by OTSUKA PHARMACEUTICAL CO., LTD. · Jul 29, 2011

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with histopathologically or clinically confirmed diagnosis of hepatocellular carcinoma
• • Patients with Child-Pugh classification A or B
• • Patients unresponsive to standard therapy or for whom standard therapy is intolerable, or for whom there is no appropriate therapy
• • Patients who are able to take oral medication
• • Patients age 20 to 79 years (inclusive) at time of informed consent
• • Patients with an ECOG performance status score of 0-2
• • Patients have the eligible organ function.
• Exclusion Criteria:
• • Patients with a primary malignant tumor
• • Patients with a history of liver transplant
• • Patients with brain metastases
• • Patients with a complication of uncontrolled
• • Patients with a psychiatric disorder that might cause difficulty in obtaining informed consent or in conducting the trial